Valuation: Atrion Corporation

Market Cap 809M 719M 671M 612M 1.15B 77.81B 1.16B 8.12B 3.15B 39.78B 3.04B 2.97B 128B P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 803M 714M 666M 607M 1.15B 77.24B 1.16B 8.06B 3.12B 39.48B 3.02B 2.95B 127B EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
503.24
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 2024-08-20
Director TitleAgeSince
Director/Board Member 53 2024-08-20
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/24 Issuer sale

Director

2,991 0.1699%
8/21/24 Issuer sale

Chief Executive Officer

98,614 5.6032%
8/21/24 Issuer sale

Director

499 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%+11.31% 809M
+0.84%-3.53%-26.95%+0.67% 167B
-0.07%-2.41%-8.89%+10.23% 111B
+0.90%+2.11%-24.36%+0.79% 105B
-1.24%-1.31%-48.43%-13.54% 74.82B
-0.24%-0.26%-0.87%+71.72% 59.11B
-0.86%+4.49%+17.49%+57.78% 51.8B
-0.71%-1.36%-7.41%-31.61% 48.5B
+0.12%+0.97%-16.40%+18.55% 40.79B
-1.01%-2.41%+29.18%-8.51% 32.54B
Average -0.07%-0.14%-8.66%+11.74% 69.1B
Weighted average by Cap. +0.10%-0.91%-15.76%+9.41%

Financials

2022 2023
Net sales 184M 163M 152M 139M 262M 17.64B 264M 1.84B 714M 9.02B 689M 674M 28.94B 169M 150M 140M 128M 241M 16.28B 244M 1.7B 658M 8.32B 636M 622M 26.71B
Net income 35.01M 31.1M 29.03M 26.46M 49.9M 3.37B 50.37M 351M 136M 1.72B 131M 129M 5.52B 19.41M 17.25M 16.1M 14.67M 27.67M 1.87B 27.93M 195M 75.49M 954M 72.88M 71.3M 3.06B
Net Debt -25.21M -22.4M -20.91M -19.06M -35.94M -2.42B -36.27M -253M -98.04M -1.24B -94.65M -92.6M -3.98B -6.02M -5.35M -4.99M -4.55M -8.58M -578M -8.66M -60.37M -23.4M -296M -22.59M -22.1M -949M
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock